Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease

[1]  D. Knockaert.  Cardiac involvement in systemic inflammatory diseases. , 2007, European heart journal.

[2]  N. Bellenger,et al.  Ischaemic and non-ischaemic cardiomyopathies--cardiac MRI appearances with delayed enhancement. , 2007, Clinical radiology.

[3]  D. Bluemke,et al.  Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: Current applications and future perspectives , 2006, Heart Failure Reviews.

[4]  Dudley J Pennell,et al.  Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[5]  K. Klingel,et al.  Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis , 2006, Circulation.

[6]  Katherine C. Wu,et al.  Delayed enhancement MR imaging: utility in myocardial assessment. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[7]  W. Nitz,et al.  Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis , 2006, Heart.

[8]  J. Magnani,et al.  Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. , 2006, American heart journal.

[9]  Robert G. Weiss,et al.  Magnetic Resonance Assessment of the Substrate for Inducible Ventricular Tachycardia in Nonischemic Cardiomyopathy , 2005, Circulation.

[10]  J. Foster,et al.  Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. , 2005, European heart journal.

[11]  H. Crijns,et al.  The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. , 2005, Chest.

[12]  R. Kim,et al.  Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. , 2005, European heart journal.

[13]  D. Pennell,et al.  Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I , 2005, Heart.

[14]  J. Schulz-Menger,et al.  Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. , 2005, Journal of the American College of Cardiology.

[15]  Olga Bondarenko,et al.  Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Raymond J Kim,et al.  Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. , 2005, Journal of the American College of Cardiology.

[17]  S. Neubauer,et al.  Subendocardial and papillary muscle involvement in a patient with Churg-Strauss syndrome, detected by contrast enhanced cardiovascular magnetic resonance , 2004, Heart.

[18]  David M Higgins,et al.  Modified Look‐Locker inversion recovery (MOLLI) for high‐resolution T1 mapping of the heart , 2004, Magnetic resonance in medicine.

[19]  K. Klingel,et al.  Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology , 2004, Circulation.

[20]  D. Pennell,et al.  Endomyocardial fibrosis in churg‐strauss syndrome , 2004, Clinical cardiology.

[21]  C H Lorenz,et al.  Differentiation of Heart Failure Related to Dilated Cardiomyopathy and Coronary Artery Disease Using Gadolinium‐Enhanced Cardiovascular Magnetic Resonance , 2003, Circulation.

[22]  J. Schaper,et al.  Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms , 2003, Circulation.

[23]  R. Kim,et al.  Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study , 2003, The Lancet.

[24]  Heiko Mahrholdt,et al.  Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[25]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[26]  R. Hruban,et al.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. , 2000, The New England journal of medicine.

[27]  H P Schultheiss,et al.  Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. , 1999, Circulation.

[28]  G. Berry,et al.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. , 1997, The New England journal of medicine.

[29]  R. Kim,et al.  Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. , 1996, Circulation.

[30]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[31]  W. Roberts,et al.  Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. , 1992, The American journal of cardiology.

[32]  B. McManus,et al.  Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. , 1987, The American journal of cardiology.

[33]  G M Bydder,et al.  Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. , 1984, AJR. American journal of roentgenology.

[34]  M. Studdert,et al.  Acute and chronic viral myocarditis. Acute diffuse nonsuppurative myocarditis and residual myocardial scarring following infection with canine parvovirus. , 1984, The American journal of pathology.

[35]  R. Okada,et al.  Interstitial cell infiltrate and myocardial fibrosis in dilated cardiomyopathy: A special type of cardiomegaly corresponding to sequelae of myocarditis , 2005, Heart and Vessels.

[36]  K. Klingel,et al.  Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. , 2003, Human pathology.

[37]  K. Takeda,et al.  Assessment of myocardial fibrosis in cardiomyopathic hamsters with gadolinium-DTPA enhanced magnetic resonance imaging. , 1998, Investigative radiology.

[38]  S. Maeda,et al.  The role of myocarditis and myocardial fibrosis in dilated cardiomyopathy. Analysis of 28 necropsy cases. , 1991, Japanese heart journal.